In the Claims:

1. **(original)** A compound of the general formula (I)



(I)

in which

X represents a hydrogen or halogen atom,

R_1 represents a hydrogen atom or a $(C_1$-$C_4)$alkyl group,

R_2 and R_3 each independently of one another represent a hydrogen atom or a $(C_1$-$C_4)$alkyl group, or else R_2 and R_3, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-$(C_1$-$C_4)$alkylpiperazinyl group, and

Het represents a heteroaromatic group of pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type which may carry one or more halogen atoms and/or one or more $(C_1$-$C_4)$alkyl and/or $(C_1$-$C_4)$alkoxy groups,

in the form of the base or an addition salt with acids, or in the hydrate or solvate form.

2. **(currently amended)** The compound according to claim 1~~, characterized in that~~ wherein X represents a halogen atom.

3. **(currently amended)** The compound according to claim 1 ~~or 2, characterized in that~~ wherein R_1 represents a $(C_1$-$C_4)$alkyl.

4. **(currently amended)** The compound according to ~~any one of claims 1 to 3, characterized in that~~ claim1wherein R_2 and R_3, each independently of one another, represent a $(C_1$-$C_4)$alkyl group or else R_2 and R_3, together with the nitrogen atom bearing them, form a pyrrolidinyl or 4-$(C_1$-$C_4)$alkylpiperazinyl group.

5. **(currently amended)** The compound according to ~~any one of claims 1 to 4, characterized in that~~ claim 1 wherein Het represents a heteroaromatic group of pyridinyl

type which may carry one or more halogen atoms and/or one or more (C_1-C_4)alkyl and/or (C_1-C_4)alkoxy groups.

6. **(currently amended)** The compound according to ~~any one of claims 1 to 5, characterized in that~~ claim 1 wherein X represents a chlorine atom and R_1 represents a methyl group.

7. **(currently amended)** A process for preparing a compound of general formula (I),



(I)

in which

X represents a hydrogen or halogen atom,

R_1 represents a hydrogen atom or a (C_1-C_4)alkyl group,

R_2 and R_3 each independently of one another represent a hydrogen atom or a (C_1-C_4)alkyl group, or else R_2 and R_3, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C_1-C_4)alkylpiperazinyl group, and

Het represents a heteroaromatic group of pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type which may carry one or more halogen atoms and/or one or more (C_1-C_4)alkyl and/or (C_1-C_4)alkoxy groups,

~~characterized in that~~ wherein the compound of general formula (IV),



(IV)

in which

X, R_1, R_2 and R_3 are as defined above,

R' represents a (C_1-C_4)alkyl group,

is reacted, in a polar solvent in the presence of acid, with a heteroarylhydrazine.

8. **(currently amended)** The process according to claim 7~~, characterized in that~~ wherein the compound of general formula (IV),



(IV)

in which

X, R_1, R_2, R_3 and R' are as defined above

is prepared by reacting a compound of general formula (III),



(III)

in which

X, R_1 and R' are as defined above,

R" represents a (C_1-C_4)alkyl group,

with an amine of general formula HNR_2R_3, in which R_2 and R_3 are as defined above, in the presence of a catalyst such as 4-(dimethylamino)pyridine.

9. **(original)** A process for preparing a compound of general formula (I),



(I)

in which

X represents a hydrogen or halogen atom,

R_1 represents a hydrogen atom or a (C_1-C_4)alkyl group,

R_2 and R_3 each independently of one another represent a hydrogen atom or a (C_1-C_4)alkyl group, or else R_2 and R_3, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C_1-C_4)alkylpiperazinyl group, and

Het represents a heteroaromatic group of pyridinyl, quinolinyl, isoquinolinyl, pyrimidinyl, pyrazinyl or pyridazinyl type which may carry one or more halogen atoms and/or one or more (C_1-C_4)alkyl and/or (C_1-C_4)alkoxy groups,

comprising the step consisting in

carrying out an N-heteroarylation reaction on a compound of general formula (V),



(V)

in which

X, R_1, R_2 and R_3 are as defined above,

in the presence of a heteroaryl halide, or else of a heteroarylboronic acid derivative and of a metal salt such as a copper salt.

10. **(currently amended)** The process according to claim 9~~, characterized in that~~ wherein compound of general formula (V),



(V)

in which

X, R_1, R_2 and R_3 are as defined above,

is prepared by reacting a compound of general formula (IV),



(IV)

in which

X, R_1, R_2, R_3 are as defined above,

R' represents a (C_1-C_4)alkyl group,

with hydrazine by heating in a solvent such as toluene in the presence of a catalytic amount of acid.

11. **(original)** A compound of the general formula (III)



(III)

in which

X represents a hydrogen or halogen atom,

R_1 represents a hydrogen atom or a (C_1-C_4)alkyl group,

R' and R", each independently of one another, represent a (C_1-C_4)alkyl group.

12. **(original)** A compound of the general formula (IV)



(IV)

in which

X represents a hydrogen or halogen atom,

R_1 represents a hydrogen atom or a (C_1-C_4)alkyl group,

R' represents a (C_1-C_4)alkyl group,

R_2 and R_3, each independently of one another, represent a hydrogen atom or a (C_1-C_4)alkyl group, or else R_2 and R_3, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C_1-C_4)alkylpiperazinyl group.

13. **(original)** A compound of the general formula (V)



(V)

in which

X represents a hydrogen or halogen atom,

R_1 represents a hydrogen atom or a (C_1-C_4)alkyl group,

R_2 and R_3, each independently of one another, represent a hydrogen atom or a (C_1-C_4)alkyl group, or else R_2 and R_3, together with the nitrogen atom bearing them, form a pyrrolidinyl, piperidinyl, morpholinyl or 4-(C_1-C_4)alkylpiperazinyl group.

14. **(cancelled)**

15. **(currently amended)** A pharmaceutical composition ~~characterized in that it comprises~~ comprising at least one compound of formula (I) according to ~~any one of claims 1 to 6,~~ claim 1 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

16. **(new)** The compound according to claim 2 wherein R_1 represents a (C_1-C_4)alkyl.

17. **(new)** The compound according to claim 2 wherein R_2 and R_3, each independently of one another, represent a (C_1-C_4)alkyl group or else R_2 and R_3, together with the nitrogen atom bearing them, form a pyrrolidinyl or 4-(C_1-C_4)alkylpiperazinyl group.

18. **(new)** The compound according to claim 3 wherein R_2 and R_3, each independently of one another, represent a $(C_1$-$C_4)$alkyl group or else R_2 and R_3, together with the nitrogen atom bearing them, form a pyrrolidinyl or 4-$(C_1$-$C_4)$alkylpiperazinyl group.

19. **(new)** The compound according to claim 2 wherein Het represents a heteroaromatic group of pyridinyl type which may carry one or more halogen atoms and/or one or more $(C_1$-$C_4)$alkyl and/or $(C_1$-$C_4)$alkoxy groups.

20. **(new)** The compound according to claim 3 wherein Het represents a heteroaromatic group of pyridinyl type which may carry one or more halogen atoms and/or one or more $(C_1$-$C_4)$alkyl and/or $(C_1$-$C_4)$alkoxy groups.

21. **(new)** The compound according to claim 4 wherein Het represents a heteroaromatic group of pyridinyl type which may carry one or more halogen atoms and/or one or more $(C_1$-$C_4)$alkyl and/or $(C_1$-$C_4)$alkoxy groups.

22. **(new)** The compound according to claim 2 wherein X represents a chlorine atom and R_1 represents a methyl group.

23. **(new)** The compound according to claim 3 wherein X represents a chlorine atom and R_1 represents a methyl group.

24. **(new)** The compound according to claim 4 wherein X represents a chlorine atom and R_1 represents a methyl group.

25. **(new)** The compound according to claim 5 wherein X represents a chlorine atom and R_1 represents a methyl group.

26. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 2 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

27. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 3 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

28. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 4 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

29. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 5 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

30. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 6 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

31. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 16 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

32. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 17 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

33. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 18 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

34. **new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 19 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

35. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 20 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

36. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 21 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

37. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 22 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

38. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 23 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

39. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 24 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

40. **(new)** A pharmaceutical composition comprising at least one compound of formula (I) according to claim 25 or a pharmaceutically acceptable salt, a hydrate or a solvate of this compound, optionally combined with at least one pharmaceutically acceptable excipient.

41. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 1.

42. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 2.

43. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 3.

44. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 4.

45. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 5.

46. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 6.

47. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 16.

48. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 17.

49. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 18.

50. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 19.

51. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 20.

52. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 21.

53. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 22.

54. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 23.

55. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 24.

56. **(new)** A method for treating pathologies in which peripheral benzodiazepine receptors are involved which comprises administering to a patient in need of such treatment an effective amount of a compound according to claim 25.